Patents Assigned to Akthelia Pharmaceuticals
  • Patent number: 9957226
    Abstract: The invention provides compounds for use in treating microbial infection in an animal. Example compounds include Pyridin-3-ylmethyl (4-((2-aminophenyl)-carbamoyl)benzyl)carbamate (“Entinostat”). The compounds can act via induction of the innate antimicrobial peptide defense system, and stimulation of autophagy.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: May 1, 2018
    Assignee: Akthelia Pharmaceuticals
    Inventors: Roger Stromberg, Hakan Ottoson, Birgitta Agerberth, Gudmundur Gudmundsson, Erica Miraglia, Frank Nylen
  • Publication number: 20160257642
    Abstract: The invention provides compounds for use in treating microbial infection in an animal. Example compounds include Pyridin-3-ylmethyl (4-((2-aminophenyl)-carbamoyl)benzyl)carbamate (“Entinostat”). The compounds can act via induction of the innate antimicrobial peptide defense system, and stimulation of autophagy.
    Type: Application
    Filed: October 29, 2014
    Publication date: September 8, 2016
    Applicant: AKTHELIA PHARMACEUTICALS
    Inventors: Roger Stromberg, Hakan Ottoson, Birgitta Agerberth, Gudmundur Gudmundsson, Erica Miraglia, Frank Nylen
  • Patent number: 9078864
    Abstract: Short chain fatty acids (SCFAs) and glycerol esters of SCFAs not previously used for that purpose are provided for use as a medicament for treating, preventing or counteracting microbial infections in animals, including humans, by stimulating the innate antimicrobial peptide defense system. Preferred compounds include phenyl substituted short chain fatty acids (SCFAs) derivatives and. Also provided are methods and compositions for treating, preventing or counteracting microbial infections, including bacterial, viral, fungal, and parasitic infections, by administration of medicaments comprising a secretagogue-effective amount of the compounds of the invention.
    Type: Grant
    Filed: December 11, 2008
    Date of Patent: July 14, 2015
    Assignee: Akthelia Pharmaceuticals
    Inventors: Gudmundur Hrafn Gudmundsson, Birgitta Agerberth, Eirikur Steingrimsson, Roger Stromberg, Raqib Rubhana
  • Publication number: 20140155358
    Abstract: The invention relates to compounds which are active as drugs for stimulating the innate antimicrobial peptide system and can be used as antimicrobial drugs. Preferred targets are infections selected from infection of the lung, trachea, urinary tract or kidney, upper GI tract and\or blood. Preferred target pathogens are selected from: Mycobacterium tuberculosis; Pseudomonas bacteria; Haemophilus influenzae; Moraxella catarrhalis. “Preferred” compounds of the invention are. Preferred compounds include 4-phenylbutyric acid or a salt of 4-phenylbutyrate, such as sodium 4-phenylbutyrate, Butyric acid or a salt of butyrate, such as sodium butyrate, or gyceryl tributyrate.
    Type: Application
    Filed: April 11, 2012
    Publication date: June 5, 2014
    Applicant: AKTHELIA PHARMACEUTICALS
    Inventors: Rubhana Raqib, Birgitta Agerberth, Gudmundur Hrafn Gudmundsson, Roger Stromberg
  • Publication number: 20110118217
    Abstract: Short chain fatty acids (SCFAs) and glycerol esters of SCFAs not previously used for that purpose are provided for use as a medicament for treating, preventing or counteracting microbial infections in animals, including humans, by stimulating the innate antimicrobial peptide defense system. Preferred compounds include phenyl substituted short chain fatty acids (SCFAs) derivatives and. Also provided are methods and compositions for treating, preventing or counteracting microbial infections, including bacterial, viral, fungal, and parasitic infections, by administration of medicaments comprising a secretagogue-effective amount of the compounds of the invention.
    Type: Application
    Filed: December 11, 2008
    Publication date: May 19, 2011
    Applicant: Akthelia Pharmaceuticals
    Inventors: Gudmundur Hrafn Gudmundsson, Birgitta Agerberth, Eirikur Steingrimsson, Roger Stromberg, Raqib Rubhana